公开(公告)号：EP2029549A2

公开(公告)日：2009-03-04

申请号：EP07765362.4

申请日：2007-06-11

申请人： Glaxo Group Limited

发明人： BARNETT, Heather, Anne ,  CAMPBELL, Ian, Baxter ,  COE, Diane, Mary ,  COOPER, Anthony, William, James ,  INGLIS, Graham, George, Adam ,  JONES, Haydn, Terence ,  KEELING, Steven, Philip ,  MACDONALD, Simon, John, Fawcett ,  MCLAY, Iain, McFarlane ,  SKONE, Philip, Alan ,  WEINGARTEN, Gordon, Gad ,  WOOLVEN, James, Michael

IPC分类号： C07D231/38 ,  A61K31/415

CPC分类号： C07D231/38

摘要： The present invention provides compounds of formula (I): a process for their preparation, to pharmaceutical compositions comprising the compounds and the preparation of said compositions, to intermediates and to use of the compounds for the manufacture of a medicament for therapeutic treatment, particularly for the treatment of inflammation, allergy and/or auto-immune conditions.

公开(公告)号：EP0973775A1

公开(公告)日：2000-01-26

申请号：EP98914960.4

申请日：1998-04-02

申请人： GLAXO GROUP LIMITED

发明人： BORTHWICK, Alan, David ,  DAVIES, David, Evan ,  EXALL, Anne, Marjorie ,  JACKSON, Deborah, Lynette ,  MASON, Andrew, McMurtrie ,  PENNELL, Andrew, Michael, Kenneth ,  RAHIM, Saad, George ,  TRIVEDI, Naimisha ,  WEINGARTEN, Gordon, Gad

IPC分类号： C07D487/04 ,  A61K31/40 ,  C07D207/14

CPC分类号： C07D487/04 ,  C07D207/14

摘要： The present invention relates to therapeutically active bicyclic compounds, processes for the manufacture of said compounds, pharmaceutical formulations containing said compounds and the use of said compounds in treatment and prophylaxis, particularly of viral infections, more particularly of infections caused by viruses which encode for a serine protease enzyme, especially viruses of the herpes family. Thus, according to one aspect of this invention, we provide a compound of general formula (I) wherein R represents H, substituted or unsubstituted C1-3 alkyl; R1 represents optionally substituted heteroaryl or fused heteroaryl with one to four heteroatoms, R5CO, R5NHCO, R5CS or R5NHCS wherein R5 may be substituted or unsubstituted and represents H, C1-6 alkyl, C1-6 alkenyl, C3-7 cylcoalkyl or fused cycloalkyl, heteroaryl or fused heteroaryl containing one to four heteroatoms, aryl or fused aryl, or arylC1-3alkyl; R2 represents R6-X- or R3CO, wherein R3 may be substituted or unsubstituted and represents (A), (B), (C), (D), (E), (F), (G), or (H), optionally including one or more further heteroatoms; R4 represents R6-X-; R6 is optionally substituted heterocyclic or fused heterocyclic with 1-4 heteroatoms, heteroaryl or fused heteroaryl with 1-4 heteroatoms, C3-10cycloalkyl or fused cycloalkyl, aryl or fused aryl; and X represents a linker group chosen from C=O, NHC=O, C(=O)C=O, CH=CHCO, CH2CO, CH2 or SO2; and salts and solvates thereof.

公开(公告)号：EP2029549B1

公开(公告)日：2010-11-10

申请号：EP07765362.4

申请日：2007-06-11

申请人： Glaxo Group Limited

发明人： BARNETT, Heather, Anne ,  CAMPBELL, Ian, Baxter ,  COE, Diane, Mary ,  COOPER, Anthony, William, James ,  INGLIS, Graham, George, Adam ,  JONES, Haydn, Terence ,  KEELING, Steven, Philip ,  MACDONALD, Simon, John, Fawcett ,  MCLAY, Iain, McFarlane ,  SKONE, Philip, Alan ,  WEINGARTEN, Gordon, Gad ,  WOOLVEN, James, Michael

IPC分类号： C07D231/38 ,  A61K31/415

CPC分类号： C07D231/38

摘要： The present invention provides compounds of formula (I): a process for their preparation, to pharmaceutical compositions comprising the compounds and the preparation of said compositions, to intermediates and to use of the compounds for the manufacture of a medicament for therapeutic treatment, particularly for the treatment of inflammation, allergy and/or auto-immune conditions.